HEXIM1 is a critical determinant of the response to tamoxifen

Oncogene

Volumn 30, Issue 33, 2011, Pages 3563-3569

  Ketchart, W ^a   Ogba, N ^a   Kresak, A ^b   Albert, J M ^b   Pink, J J ^a   Montano, M M ^a  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

breast cancer; estrogen receptor; HEXIM1; tamoxifen

Indexed keywords

CYCLIN T1; ESTROGEN RECEPTOR ALPHA; HEXAMETHYLENE BIS ACETAMIDE INDUCIBLE PROTEIN 1; PROTEIN; RNA POLYMERASE II; SERINE; TAMOXIFEN; UNCLASSIFIED DRUG;

ARTICLE; ATTENUATION; BREAST CANCER; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INHIBITION KINETICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN T; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; NEOPLASM RECURRENCE, LOCAL; PHOSPHORYLATION; RNA POLYMERASE II; RNA-BINDING PROTEINS; TAMOXIFEN; TRANSCRIPTIONAL ELONGATION FACTORS;

EID: 80051796258     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.76     Document Type: Article

References (23)

1. Anderson H, Bulun S, Smith I, Dowsett M. (2007). Predictors of response to aromatase inhibitors. J Steroid Biochem Mol Biol 106: 49-54. (Pubitemid 47362644)
2. Cleator SJ, Ahamed E, Coombes RC, Palmieri C. (2009). A 2009 update on the treatment of patients with hormone receptor-positive breast cancer. Clin Breast Cancer 9(Suppl 1): S6-S17.
3. Deroo BJ, Korach KS. (2006). Estrogen receptors and human disease. J Clin Invest 116: 561-570. (Pubitemid 43326860)
4. Gruber CJ, Tschugguel W, Schneeberger C, Huber JC. (2002). Production and actions of estrogens. N Engl J Med 346: 340-352.
5. Hurvitz SA, Pietras RJ. (2008). Rational management of endocrine resistance in breast cancer. Cancer 9: 2385-2397.
6. Kusuhara M, Nagasaki K, Kimura K, Maass N, Manabe T, Ishikawa S et al. (1999). Cloning of hexamethylene-bis-acetamide-inducible transcript, HEXIM1, in human vascular smooth muscle cells. Biomed Res 20: 273-279. (Pubitemid 30128957)
7. Lahusen T, Henke RT, Kagan BL, Wellstein A, Riegel AT. (2009). The role and regulation of the nuclear receptor co-activator AIB1 in breast cancer. Breast Cancer Res Treat 116: 225-237.
8. Lavinsky RM, Jepsen K, Heinzel T, Torchia J, Mullen TM, Schiff R et al. (1998). Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes. Proc Natl Acad Sci USA 95: 2920-2925.
9. Lewis JS, Jordan VC. (2005). Selective estrogen receptor modulators (SERMs): mechanisms of anticarcinogenesis and drug resistance. Mutat Res 591: 247-263. (Pubitemid 41654853)
10. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K et al. (1995). The nuclear receptor superfamily: the second decade. Cell 83: 835-839.
11. Musgrove EA, Sutherland RL. (1994). Cell cycle control by steroid hormones. Semin Cancer Biol 5: 381-389. (Pubitemid 124006791)
12. Ogba N, Chaplin LJ, Doughman YQ, Fujinaga K, Montano MM. (2008). HEXIM1 regulates 17beta-estradiol/estrogen receptor-alpha-mediated expression of cyclin D1 in mammary cells via modulation of P-TEFb. Cancer Res 68: 7015-7024.
13. Osborne CK. (1998). Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618. (Pubitemid 28536137)
14. Riggins RB, Schrecengost RS, Guerrero MS, Bouton AH. (2007). Pathways to tamoxifen resistance. Cancer Lett 256: 1-24. (Pubitemid 47333324)
15. Ring A, Dowsett M. (2004). Mechanisms of tamoxifen resistance. Endocr Relat Cancer 11: 643-658. (Pubitemid 40065543)
16. Scott DJ, Parkes AT, Ponchel F, Cummings M, Poola I, Speirs V. (2007). Changes in expression of steroid receptors, their downstream target genes and their associated co-regulators during the sequential acquisition of tamoxifen resistance in vitro. Int J Oncol 31: 557-565.
17. Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA et al. (1998). The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95: 927-937. (Pubitemid 29019045)
18. Webb P, Nguyen P, Kushner PJ. (2003). Differential SERM effects on corepressor binding dictate ERalpha activity in vivo. J Biol Chem 278: 6912-6920. (Pubitemid 36800683)
19. Wittmann BM, Fujinaga K, Deng H, Ogba N, Montano MM. (2005). The breast cell growth inhibitor, estrogen down regulated gene 1, modulates a novel functional interaction between estrogen receptor alpha and transcriptional elongation factor cyclin T1. Oncogene 24: 5576-5588. (Pubitemid 43119352)
20. Wittmann BM, Wang N, Montano MM. (2003). Identification of a novel inhibitor of breast cell growth that is down-regulated by estrogens and decreased in breast tumors. Cancer Res 63: 5151-5158. (Pubitemid 37022657)
21. Yager JD, Davidson NE. (2006). Estrogen carcinogenesis in breast cancer. N Engl J Med 354: 270-282.
22. Yik JH, Chen R, Nishimura R, Jennings JL, Link AJ, Zhou Q. (2003). Inhibition of P-TEFb (CDK9/Cyclin T) kinase and RNA poly-merase II transcription by the coordinated actions of HEXIM1 and 7SK snRNA. Mol Cell 12: 971-982. (Pubitemid 37352789)
23. Zwart W, Rondaij M, Jalink K, Sharp ZD, Mancini MA, Neefjes J et al. (2009). Resistance to antiestrogen arzoxifene is mediated by overexpression of cyclin D1. Mol Endocrinol 23: 1335-1345.